☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
lower respiratory tract disease
Janssen Initiates P-III EVERGREEN Study of RSV Vaccine for the Treatment of Lower Respiratory Tract Disease Due to Respiratory Syn...
September 30, 2021
GSK Reports P-III Trial (AReSVi-006) Results of Arexvy for Preventing Lower Respiratory Tract Disease Caused by Respiratory Syncyt...
June 22, 2023
GSK’s Arexvy Receives EC’s Approval for the Prevention of Lower Respiratory Tract Disease in Individuals Aged ≥60 Years
June 7, 2023
GSK’s Arexvy Receives the US FDA’s Approval for the Prevention of Lower Respiratory Tract Disease in Individuals Aged ≥60 Years
May 4, 2023
AstraZeneca and Sanofi’s Beyfortus (nirsevimab) Receives the EC’s Approval for the Prevention of RSV Lower Respiratory Tract Disea...
November 4, 2022
AstraZeneca and Sanofi’s Beyfortus (nirsevimab) Receive EMA's CHMP Positive Opinion for the Prevention of RSV Lower Respiratory Tr...
September 16, 2022
Janssen Initiates P-III EVERGREEN Study of RSV Vaccine for the Treatment of Lower Respiratory Tract Disease Due to Respiratory Syn...
September 30, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.